摘要
目的 :观察鬼臼噻吩苷 (VM 2 6 )联合方案 (CVMxP)对非霍奇金恶性淋巴瘤病人的疗效和毒副反应。方法 :CVMxP方案 (环磷酰胺 5 0 0mg/m2 ivd1,VM 2 6 10 0mg/m2 ivd1;米托蒽醌 10mg/m2 ivd 1,强的松 40mg/m2 pod1— 5。 2 1天为 1周期 ,共用 2周期。)治疗有病理学证实的非霍奇金恶性淋巴瘤病人 ,观察疗效和毒副反应。结果 :可评价疗效的病例为 2 0例 ,病理类型为中高度恶性 ,临床分期为Ⅱ—Ⅳ期。总有效率 75 % ,完全缓解 (CR)率 2 5 %。初治病人CR率 5 0 % (4 /8) ,复治病人仅 1例获CR(1/12 )。初治病人 8例全部有效 ,复治病人有效率 5 8 3% (7/12 )。曾经CHOP方案治疗的病人有效率 6 3 6 %。主要毒副反应为骨髓抑制 ,80 %病人有Ⅰ—Ⅳ度白细胞减少 ,Ⅲ、Ⅳ度白细胞减少占 2 0 %。血小板减少程度较轻。结论 :CVMxP联合方案是治疗非霍奇金恶性淋巴瘤安全有效的方案 ,和文献报道的其他方案具可比性。
Purpose:To investigate the efficacy and the side effects of CVMxP for patients with non Hodgkin′s lymphoma.Methods:Patients with pathologicaly diagnosed non Hodgkin′s lymphoma were treated with two cycles of chemotherapy (cyclophosphamide 500?mg/m 2 iv d?1;teniposide 100?mg/m 2 iv d1;mitoxantrone 10?mg/m 2 iv d?1;prednisone 40?mg/m 2 po d?1—5. The cycle was repeated on d?21).Results:20 patients were evaluable. The overall response rate was 75%, the complete response rate was 25%. 50% previously untreated patients had complete response. The response rate of patients previously treated with CHOP was 63.6%. Twenty percent of patients had Grade 3 to 4 neutropenia. Conclusions:CVMxP results in a complete response rate comparable to those reported previously in the literature, and is effective in more than half of the patients treated with CHOP.
出处
《中国癌症杂志》
CAS
CSCD
2000年第3期214-215,共2页
China Oncology
